SurModics (SRDX) Tops Q4 EPS by 11c; Approves Additional $20M Stock Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
SurModics Reports Fourth Quarter Fiscal 2015 Results
November 10, 2015 7:35 AM ESTGAAP Revenue Growth of 13% to $17.4 Million and GAAP EPS of $0.22 Non-GAAP Revenue Up 8% and Non-GAAP EPS of $0.30 FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon Increase in Share Repurchase Authorization to $30.0 Million Fiscal 2016 Guidance Outlined
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2015 fourth... More
